Leeds spinout adsilico raises £10m to test heart implants on AI virtual patients

adsilico, a University of Leeds spinout, has raised a £10m Series A led by PXN Ventures, with existing investors Northern Gritstone and Parkwalk. It uses AI to build virtual patients for testing heart implants, as BusinessCloud reported.

What it does

The company’s Virtual Chimera platform uses generative AI to build virtual hearts and blood vessels from anonymised scans. It then runs physics-based simulations of how a device performs across virtual populations, varied by age, sex, ethnicity, body size and disease, under clinical oversight.

In plain terms, a device maker can see how a stent or valve behaves in thousands of different bodies before it goes anywhere near a human trial.

The problem it’s going after

Real trials don’t look like the people who end up with the device. BusinessCloud cites a JAMA Internal Medicine study of 195 high-risk implant trials, where women made up 33% of participants, falling to 29% in cardiovascular trials.

A virtual population can be built to match the real one. That’s the commercial case, and it’s a strong one, because problems found in simulation are far cheaper than problems found in a trial.

Duncan Johnson of Northern Gritstone made the same point: the technology helps manufacturers spot problems before costly human trials.

Who’s behind it

adsilico was founded in 2024 by CEO Sheena Macpherson, with Dr Nishant Ravikumar and Dr Zeike Taylor. It’s based at Nexus, the University of Leeds innovation centre.

Where the money goes

The plan is to extend the heart work, move into brain devices such as flow diverters for aneurysms, and grow the team from 14 to 34.

It’s the second Northern university spinout round PXN has led or co-led this week, after Manchester’s Concretene. Two years from founding to a £10m Series A is quick for medtech, and 20 new jobs in Leeds is the part I’d hold them to.


The North is FU7URE’s briefing on the people, capital and infrastructure reshaping the North of England. Subscribe to the free newsletter to get it in your inbox.

Leave a Reply

Your email address will not be published. Required fields are marked *